ScholarIQanswers from OpenAlex & ORCID
Michael B. Andrews
ResearcherPublications, citations & collaboration network
Michael B. Andrews is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael B. Andrews have?
ScholarIQindexed works
Michael B. Andrews has 16 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael B. Andrews have?
ScholarIQcitation count
Michael B. Andrews has 116 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael B. Andrews?
ScholarIQh-index
Michael B. Andrews has an h-index of 3 in OpenAlex.
What is the i10-index of Michael B. Andrews?
ScholarIQi10-index
Michael B. Andrews has an i10-index of 2 in OpenAlex.
What is the ORCID of Michael B. Andrews?
ScholarIQorcid
The ORCID for Michael B. Andrews is on the source record.
What is the OpenAlex record for Michael B. Andrews?
ScholarIQopenalex
The OpenAlex for Michael B. Andrews is on the source record.
What are the most-cited papers on Michael B. Andrews?
ScholarIQmost cited works
Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer.
John D. Hainsworth, Michael B. Andrews, David H. Johnson, Filippo Greco
Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin’s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
John D. Hainsworth, Sharlene Litchy, Lisa H. Morrissey, Michael B. Andrews, Manuel Grimaldi, Matthew J. McCarty, F. Anthony Greco
Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database
Michael B. Andrews, Douglas G. Adler
Safety of the contrast enhancement agent sulfur hexafluoride in ultrasound: Analysis of the Federal Drug Administration Adverse Event Reporting System database
Courtney Walker, Michael B. Andrews, Douglas G. Adler
Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications
Praneeth Kudaravalli, Michael B. Andrews, Douglas G. Adler